Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilo Post-STIM: nilotinib in CML patients with molecular relapse after imatinib discontinuation
2012-004048-31Phase 2Active
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoints: Rescue efficacy of nilotinib after molecular relapse post-imatinib discontinuation and Duration of complete molecular response after nilotinib discontinuation. Started Jan 2021; status: active.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2012-004048-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004048-31.